Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya

Tropical Medicine and International Health

Volumn 14, Issue 4, 2009, Pages 450-457

  Black, Carla L ^a   Steinauer, Michelle L ^b   Mwinzi, Pauline N M ^c   Evan Secor, W ^d   Karanja, Diana M S ^c   Colley, Daniel G ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Drug resistance; Praziquantel; Schistosomiasis

Indexed keywords

PRAZIQUANTEL;

DRUG; DRUG RESISTANCE; INFECTIOUS DISEASE; MULTIVARIATE ANALYSIS; NUMERICAL MODEL; OCCUPATIONAL EXPOSURE; POPULATION STRUCTURE; REGRESSION ANALYSIS; SNAIL;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE TRANSMISSION; DRUG EFFICACY; EGG; HUMAN; KENYA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PARASITE IDENTIFICATION; PARASITE PREVALENCE; REPEATED DRUG DOSE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SINGLE DRUG DOSE; SNAIL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANIMALS; ANTHELMINTICS; DRUG RESISTANCE; HIV INFECTIONS; HUMANS; LIVER DISEASES, PARASITIC; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; PARASITE EGG COUNT; PRAZIQUANTEL; SCHISTOSOMIASIS MANSONI;

AFRICA; EAST AFRICA; KENYA; SUB-SAHARAN AFRICA;

GASTROPODA; SCHISTOSOMA MANSONI;

EID: 62449214951     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2009.02234.x     Document Type: Article

References (26)

1. Botros S, Sayed H, Amer H, El-Ghannam G, Bennett JL Day TA (2005) Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. International Journal of Parasitology 35, 787 791.
2. Brindley PJ Sher A (1987) The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependent on host antibody response. Journal of Immunology 139, 215 220.
3. Chitsulo L, Engels D, Montresor A Savioli L (2007) The global status of schistosomiasis and its control. Acta Tropica 77, 41 51.
4. Cioli D (2000) Praziquantel: is there real resistance and are there alternatives? Current Opinion in Infectious Diseases 13, 659 663.
5. Doenhoff MJ, Sabah AAA, Fletcher C, Webbe G Bain J (1987) Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice. Transactions of the Royal Society of Tropical Medicine and Hygiene 81, 947 951.
6. Doenhoff MJ, Kusel JR, Coles GC Cioli D (2002) Resistance of Schistosoma mansoni to praziquantel: is there a problem? Transactions of the Royal Society of Tropical Medicine and Hygiene 96, 465 469.
7. Feng ZL, Curtis J Minchella DJ (2001) The influence of drug treatment on the maintenance of schistosome genetic diversity. Journal of Mathematical Biology 43, 52 68.
8. Fenwick A, Savioli L, Engels D, Bergquist NR Todd MH (2003) Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends in Parasitology 19, 509 515.
9. Fulford AJ, Butterworth AE, Ouma JH Sturrock RF (1995) A statistical approach to schistosome population dynamics and estimation of the life span of Schistosoma mansoni in man. Parasitology 110 (Pt 3 307 316.
10. Garcia N, Isturiz G, Aular S Incani RN (2006) The efficacy of human schistosomide treatment may depend on the rate of transmission. Parasitology Research 98, 545 549.
11. Gryseels B, Mbaye A, De Vlas SJ et al. (2001) Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Tropical Medicine and International Health 6, 864 873.
12. Harnett W Kusel JR (1986) Increased exposure of parasite antigens at the surface of adult male Schistosoma mansoni exposed to praziquantel in vitro. Parasitology 93, 401 405.
13. Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF Bennett JL (1996) Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. American Journal of Tropical Medicine and Hygiene 55, 214 218.
14. Kabatereine NB, Kemijumbi J Ouma JH (2003) Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert, Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene 97, 599 603.
15. Karanja DMS, Boyer AE, Strand M et al. (1998) Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfected with human immunodeficiency virus-1 American Journal of Tropical Medicine and Hygiene 59, 307 311.
16. Karanja DMA, Hightower AW, Colley DG et al. (2002) Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study. Lancet 360, 592 596.
17. Kariuki HC, Clennon JA, Brady MS et al. (2004) Distribution patterns and cercarial shedding of Bulinus nasutus and other snails in the Msambweni area, Coast Province, Kenya. American Journal of Tropical Medicine and Hygiene 70, 449 456.
18. King CH, Muchiri EM Ouma JH (2000) Evidence against rapid emergence of praziquantel reistance in Schistosoma haematobium, Kenya. Emerging Infectious Diseases 6, 585 594.
19. Modha J, Lambertucci JR, Doenhoff MJ McClaren DJ (1990) Immune dependence of schistosomicidal chemotherapy: an untrastructural study of Schistosoma mansoni adult worms exposed to praziquantel and immune serum in vivo. Parasite Immunology 12, 321 334.
20. Mwinzi PNM, Karanja DMS, Colley DG, Orago ASS Secor WE (2001) Cellular immune response of schistosomiasis patients are altered by Human Immunodeficiency Virus-1 co-infection. Journal of Infectious Diseases 84, 488 496.
21. Mwinzi PNM, Ganley-Leal L, Black CL, Secor WE, Karanja DMS Colley DG (2009) Circulating CD23+ B cell subset correlates with the development of resistance to Schistosoma mansoni reinfection in occupationally exposed adults who have undergone multiple treatments. Journal of Infectious Diseases 199, 272 279.
22. Raso G, N'Goran EK, Toty A et al. (2004) Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Cote d'Ivoire. Transactions of the Royal Society of Tropical Medicine and Hygiene 98, 18 27.
23. Steinauer ML, Mwangi IN, Maina GM et al. (2008) Interactions between natural populations of human and rodent schistosomes in the Lake Victoria region of Kenya: a molecular epidemiological approach. PLoS Neglected Tropical Diseases 2, e222.
24. Sturrock RF, Kinyanjui H, Thiongo FW et al. (1990) Chemotherapy-based control of schistosomiasis haematobia. 3. Snail studies monitoring the effect of chemotherapy on transmission in the Msambweni area, Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene 84, 257 261.
25. Van Lieshout L, Stelma FF, Guisse F et al. (1999) The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal. American Journal of Tropical Medicine and Hygiene 61, 760 765.
26. Yu DB, Li Y, Sleigh AC et al. (2001) Efficacy of praziquantel against Schistosoma japonicum: field evaluation in an area with repeated chemotherapy compared with a newly identified endemic focus in Hunan, China. Transactions of the Royal Society of Tropical Medicine and Hygiene 95, 537 541.